Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMMP Prima BioMed	$1.61 -3.0%	$1.79	$1.32 ▼ $2.80	$235.12M	1.76	207,481 shs	135,546 shs
INZY Inozyme Pharma	$3.98 -0.3%	$2.55	$0.72 ▼ $6.24	$257.28M	2.29	889,039 shs	698,765 shs
TSVT 2seventy bio	$5.00	$4.99	$2.29 ▼ $5.30	$266.15M	1.04	642,396 shs	N/A
VTGN VistaGen Therapeutics	$2.06 -13.4%	$2.31	$1.90 ▼ $4.21	$60.06M	0.7	173,002 shs	415,107 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMMP Prima BioMed	0.00%	-6.94%	-19.90%	-14.36%	-37.35%
INZY Inozyme Pharma	0.00%	0.00%	+0.76%	+308.58%	-9.55%
TSVT 2seventy bio	0.00%	0.00%	0.00%	+1.01%	+28.53%
VTGN VistaGen Therapeutics	0.00%	-11.21%	-21.67%	-26.16%	-37.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMMP Prima BioMed	1.0163 of 5 stars	3.5	1.0	0.0	0.0	1.0	0.0	0.0
INZY Inozyme Pharma	2.6456 of 5 stars	4.2	3.0	0.0	0.0	0.6	2.5	0.0
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	1.1218 of 5 stars	0.0	2.0	0.0	0.0	3.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMMP Prima BioMed	3.00	Buy	$7.00	334.78% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	195.23% Upside
TSVT 2seventy bio	2.00	Hold	$5.00	N/A
VTGN VistaGen Therapeutics	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest VTGN, IMMP, TSVT, and INZY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	VTGN VistaGen Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/10/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
4/24/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/10/2025	INZY Inozyme Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/8/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMMP Prima BioMed	$5.14M	45.74	N/A	N/A	$1.05 per share	1.53
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A
TSVT 2seventy bio	$48.37M	5.50	N/A	N/A	$5.04 per share	0.99
VTGN VistaGen Therapeutics	$490K	122.59	N/A	N/A	$4.23 per share	0.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)
TSVT 2seventy bio	-$217.57M	-$0.10	N/A	N/A	N/A	-207.25%	-53.65%	-23.67%	8/6/2025 (Estimated)
VTGN VistaGen Therapeutics	-$29.36M	-$1.48	N/A	N/A	N/A	-6,777.08%	-58.88%	-52.38%	8/11/2025 (Estimated)

Latest VTGN, IMMP, TSVT, and INZY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/17/2025	Q4 2025	VTGN VistaGen Therapeutics	-$0.53	-$0.43	+$0.10	-$0.43	$0.18 million	($0.01) million
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/7/2025	Q1 2025	TSVT 2seventy bio	-$0.10	$0.01	+$0.11	$0.01	$13.96 million	$22.94 million
3/25/2025	Q4 2024	TSVT 2seventy bio	-$0.23	-$0.31	-$0.08	-$0.37	$12.84 million	$2.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMMP Prima BioMed	N/A	18.86	N/A
INZY Inozyme Pharma	0.65	2.19	2.19
TSVT 2seventy bio	N/A	4.95	4.95
VTGN VistaGen Therapeutics	N/A	6.51	9.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMMP Prima BioMed	2.32%
INZY Inozyme Pharma	88.30%
TSVT 2seventy bio	93.90%
VTGN VistaGen Therapeutics	78.39%

Insider Ownership

Company	Insider Ownership
IMMP Prima BioMed	3.07%
INZY Inozyme Pharma	12.18%
TSVT 2seventy bio	7.20%
VTGN VistaGen Therapeutics	1.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMMP Prima BioMed	2,021	146.04 million	141.56 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable
TSVT 2seventy bio	440	53.23 million	47.87 million	Optionable
VTGN VistaGen Therapeutics	40	29.16 million	28.49 million	Optionable

VTGN, IMMP, TSVT, and INZY Headlines

Recent News About These Companies

VistaGen Therapeutics (NASDAQ:VTGN) Earns Outperform Rating from William Blair

June 20 at 1:31 AM | americanbankingnews.com

Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges

June 19 at 8:25 PM | tipranks.com

What is William Blair's Forecast for VTGN Q1 Earnings?

June 19 at 7:40 AM | marketbeat.com

VistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William Blair

June 18 at 10:11 PM | marketbeat.com

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...

June 18 at 4:22 AM | finance.yahoo.com

Vistagen Therapeutics Reports Progress in Clinical Trials

June 18 at 12:26 AM | tipranks.com

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

June 17 at 7:10 PM | seekingalpha.com

Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

June 17 at 5:06 PM | marketbeat.com

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

June 17 at 4:30 PM | businesswire.com

Insights into VistaGen Therapeutics's Upcoming Earnings

June 16, 2025 | benzinga.com

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For

June 16, 2025 | gurufocus.com

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

June 12, 2025 | businesswire.com

Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday

June 3, 2025 | marketbeat.com

Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Above 50 Day Moving Average - Should You Sell?

May 28, 2025 | marketbeat.com

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025 | businesswire.com

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

April 17, 2025 | businesswire.com

Why Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 10.10%

April 8, 2025 | aaii.com

VistaGen at Stifel 2025: Pioneering Acute SAD Treatment

March 20, 2025 | investing.com

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

March 19, 2025 | businesswire.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript

February 15, 2025 | msn.com

VistaGen’s Earnings Call: Progress and Challenges

February 14, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN, IMMP, TSVT, and INZY Company Descriptions

Prima BioMed NASDAQ:IMMP

$1.61 -0.05 (-3.01%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.64 +0.03 (+1.86%)

As of 06/18/2025 07:26 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Inozyme Pharma NASDAQ:INZY

$3.98 -0.01 (-0.25%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.98 +0.00 (+0.13%)

As of 06/18/2025 04:35 PM Eastern

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

2seventy bio NASDAQ:TSVT

$5.00 0.00 (0.00%)

As of 05/13/2025

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

VistaGen Therapeutics NASDAQ:VTGN

$2.06 -0.32 (-13.45%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.08 +0.02 (+0.97%)

As of 06/18/2025 07:58 PM Eastern

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time